[1] Agustoni F, Suda K, Yu H, Ren SX, Rivard CJ, Ellison K, et al. EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis. Cancer Treatment Reviews. 2019;72:15-27.
[2] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. Ca-a Cancer Journal for Clinicians. 2021;71(1):7-33.
[3] Mok TS, Wu YL, F.A.C.S, Thongprasert S, Yang CH, Chu DT, et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma. The New England Journal of Medicine.2009;361:947-57.
[4] Shepherd FA, Pereira JR, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer. The New England Journal of Medicine. 2005;353:123-32.
[5] Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology. 2012;13(3):239-46.
[6] Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. The New England Journal of Medicine. 2009;361(10):958-67.
[7] Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nature Reviews Cancer. 2013;13(10):714-26.
[8] Obenauf AC, Zou YL, Ji AL, Vanharanta S, Shu WP, Shi HB, et al. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature. 2015;520(7547):368-72.
[9] Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng WG, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nature Medicine. 2015;21(8):938-45.
[10] Zhan HX, Zhou B, Cheng YG, Xu JW, Wang L, Zhang GY, et al. Crosstalk between stromal cells and cancer cells in pancreatic cancer: New insights into stromal biology. Cancer Letters. 2017;392:83-93.
[11] Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52-67.
[12] Eckstein N, Servan K, Hildebrandt B, Pölitz A, von Jonquières G, Wolf-Kümmeth S, et al. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res. 2009;69(7):2996-3003.
[13] Meads MB, Hazlehurst LA, Dalton WS. The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance. Clinical Cancer Research. 2008;14(9):2519-26.
[14] Andrews TS, Hemberg M. Identifying cell populations with scRNASeq. Molecular Aspects of Medicine. 2018;59:114-22.
[15] Niederst MJ, Engelman JA. Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer. Science Signaling. 2013;6(294).
[16] Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nature Reviews Cancer. 2017;17(11):637-58.
[17] Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Seminars in Cancer Biology. 2020;61:167-79.
[18] Lupia M, Cavallaro U. Ovarian cancer stem cells: still an elusive entity? Mol Cancer. 2017;16(1):64.
[19] Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, et al. Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer. Clinical Cancer Research. 2012;18(3):869-81.
[20] Tang F, Barbacioru C, Wang Y, Nordman E, Lee C, Xu N, et al. mRNA-Seq whole-transcriptome analysis of a single cell. Nat Methods. 2009;6(5):377-82.
[21] Ling B, Huang ZL, Huang SY, Qian L, Li GL, Tang QL. Microenvironment Analysis of Prognosis and Molecular Signature of Immune-Related Genes in Lung Adenocarcinoma. Oncology Research. 2021;28(6):561-78.
[22] Chien J, Kuang R, Landen C, Shridhar V. Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Front Oncol. 2013;3:251.
[23] Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nature Communications. 2013;4:2612.
[24] Jia D, Li SL, Li DL, Xue HP, Yang D, Liu Y. Mining TCGA database for genes of prognostic value in glioblastoma microenvironment. Aging-Us. 2018;10(4):592-605.
[25] Cao R, Yuan L, Ma B, Wang G, Tian Y. Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC). Cancer Immunol Immunother. 2021;70(1):1-18.
[26] Cutolo M, Sulli A, Paolino S, Pizzorni C. CTLA-4 blockade in the treatment of rheumatoid arthritis: an update. Expert Review of Clinical Immunology. 2016;12(4):417-25.
[27] Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321-30.
[28] Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. Journal for Immunotherapy of Cancer. 2019;7(1):306.
[29] Liu R, Yang F, Yin JY, Liu YZ, Zhang W, Zhou HH. Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study. Frontiers in Immunology. 2021;12.
[30] Qi YY, Chang Y, Wang ZW, Chen LL, Kong YY, Zhang PP, et al. Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response. Cancer Immunology Immunotherapy. 2019;68(12):2067-80.
[31] Kumar AT, Knops A, Swendseid B, Martinez-Outschoom U, Harshyne L, Philp N, et al. Prognostic Significance of Tumor-Associated Macrophage Content in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. Front Oncol. 2019;23;9:656.
[32] Bercovici N, MV Guérin, Trautmann A, Donnadieu E. The remarkable plasticity of macrophages: a chance to fight cancer. Frontiers in Immunology.2019;10:1563.
[33] Fibrinogen Studies Collaboration. Measures to assess the prognostic ability of the stratified Cox proportional hazards model. Stat Med. 2009;28(3):389-411.
[34] Zhang HH, Lu W. Adaptive Lasso for Cox's proportional hazards model. Biometrika.2007;94(3):691-703.
[35] Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019;572(7769):392-6.
[36] Chen GY, Tang J, Zheng P, Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science. 2009;323(5922):1722-5.
[37] Mu WJ, Hu CB, Zhang HB, Qu ZQ, Cen J, Qiu ZX, et al. miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression. Cell Research. 2015;25(4):477-95.
[38] Aissa AF, Islam A, Ariss MM, Go CC, Rader AE, Conrardy RD, et al. Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer. Nature Communications. 2021;12(1).
[39] Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nature Biotechnology. 2018;36(5):411-20.
[40] Hight SK, Mootz A, Kollipara RK, McMillan E, Yenerall P, Otaki Y, et al. An in vivo functional genomics screen of nuclear receptors and their co-regulators identifies FOXA1 as an essential gene in lung tumorigenesis. Neoplasia. 2020;22(8):294-310.
[41] Tang H, Xiao GH, Behrens C, Schiller J, Allen J, Chow CW, et al. A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non-Small Cell Lung Cancer Patients. Clinical Cancer Research. 2013;19(6):1577-86.
[42] Leon LM, Gautier M, Allan R, Ilie M, Nottet N, Pons N, et al. The nuclear hypoxia-regulated NLUCAT1 long non-coding RNA contributes to an aggressive phenotype in lung adenocarcinoma through regulation of oxidative stress. Oncogene. 2019;38(46):7146-65.
[43] Ruden DM, Chen L, Possidente D, Possidente B, Rasouli P, Wang L, et al. Genetical toxicogenomics in Drosophila identifies master-modulatory loci that are regulated by developmental exposure to lead. Neurotoxicology. 2009;30(6):898-914.
[44] Wang ZH, Guo XP, Gao L, Wang Y, Ma WB, Xing B. Glioblastoma cell differentiation trajectory predicts the immunotherapy response and overall survival of patients. Aging-Us. 2020;12(18):18297-321.
[45] Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361-87.
[46] Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-50.
[47] Thissen D, Steinberg L, Kuang D. Quick and Easy Implementation of the Benjamini-Hochberg Procedure for Controlling the False Positive Rate in Multiple Comparisons. Journal of Educational & Behavioral Statistics.2002;27(1):77-83.